Annual Cash & Cash Equivalents
$2.56 M
-$2.69 M-51.26%
December 31, 2023
Summary
- As of February 8, 2025, AGRX annual cash & cash equivalents is $2.56 million, with the most recent change of -$2.69 million (-51.26%) on December 31, 2023.
- During the last 3 years, AGRX annual cash & cash equivalents has fallen by -$11.91 million (-82.32%).
Performance
AGRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.85 M
+$233.00 K+8.91%
June 1, 2024
Summary
- As of February 8, 2025, AGRX quarterly cash and cash equivalents is $2.85 million, with the most recent change of +$233.00 thousand (+8.91%) on June 1, 2024.
- Over the past year, AGRX quarterly cash and cash equivalents has stayed the same.
Performance
AGRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AGRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -51.3% | 0.0% |
| 3 y3 years | -82.3% | 0.0% |
| 5 y5 years | -67.4% | 0.0% |
AGRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -86.6% | at low | -85.1% | -10.2% |
| 5 y | 5-year | -92.6% | at low | -97.0% | -10.2% |
| alltime | all time | -94.8% | -17.1% | -97.0% | -25.6% |
Agile Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2024 | - | $2.85 M(+8.9%) |
| Mar 2024 | - | $2.62 M(+2.3%) |
| Dec 2023 | $2.56 M(-51.3%) | $2.56 M(-11.0%) |
| Sep 2023 | - | $2.87 M(+3.2%) |
| Jun 2023 | - | $2.79 M(-37.1%) |
| Mar 2023 | - | $4.43 M(-15.6%) |
| Dec 2022 | $5.25 M(-72.6%) | $5.25 M(-14.6%) |
| Sep 2022 | - | $6.14 M(-52.8%) |
| Jun 2022 | - | $13.03 M(+248.0%) |
| Mar 2022 | - | $3.74 M(-80.4%) |
| Dec 2021 | $19.14 M(+32.4%) | $19.14 M(+29.9%) |
| Sep 2021 | - | $14.73 M(-43.6%) |
| Jun 2021 | - | $26.12 M(+58.6%) |
| Mar 2021 | - | $16.46 M(+13.8%) |
| Dec 2020 | $14.46 M(-58.1%) | $14.46 M(-40.1%) |
| Sep 2020 | - | $24.16 M(-38.7%) |
| Jun 2020 | - | $39.45 M(-58.0%) |
| Mar 2020 | - | $93.92 M(+172.4%) |
| Dec 2019 | $34.48 M(+339.2%) | $34.48 M(+87.7%) |
| Sep 2019 | - | $18.37 M(+73.5%) |
| Jun 2019 | - | $10.59 M(-8.4%) |
| Mar 2019 | - | $11.56 M(+47.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $7.85 M(-78.2%) | $7.85 M(-53.6%) |
| Sep 2018 | - | $16.93 M(-24.7%) |
| Jun 2018 | - | $22.46 M(-20.7%) |
| Mar 2018 | - | $28.34 M(-21.2%) |
| Dec 2017 | $35.95 M(-26.3%) | $35.95 M(-17.9%) |
| Sep 2017 | - | $43.81 M(+29.1%) |
| Jun 2017 | - | $33.94 M(-18.7%) |
| Mar 2017 | - | $41.74 M(-14.4%) |
| Dec 2016 | $48.75 M(+41.7%) | $48.75 M(-5.7%) |
| Sep 2016 | - | $51.67 M(-12.8%) |
| Jun 2016 | - | $59.22 M(-9.6%) |
| Mar 2016 | - | $65.50 M(+90.4%) |
| Dec 2015 | $34.40 M(-14.4%) | $34.40 M(-12.7%) |
| Sep 2015 | - | $39.40 M(-15.1%) |
| Jun 2015 | - | $46.41 M(-13.8%) |
| Mar 2015 | - | $53.87 M(+34.1%) |
| Dec 2014 | $40.18 M(+1795.7%) | $40.18 M(-12.0%) |
| Sep 2014 | - | $45.68 M(-14.6%) |
| Jun 2014 | - | $53.49 M(+1677.2%) |
| Mar 2014 | - | $3.01 M(+42.0%) |
| Dec 2013 | $2.12 M(-89.4%) | $2.12 M |
| Dec 2012 | $20.01 M | - |
FAQ
- What is Agile Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Agile Therapeutics?
- What is Agile Therapeutics annual cash & cash equivalents year-on-year change?
- What is Agile Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Agile Therapeutics?
- What is Agile Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Agile Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of AGRX is $2.56 M
What is the all time high annual cash & cash equivalents for Agile Therapeutics?
Agile Therapeutics all-time high annual cash & cash equivalents is $48.75 M
What is Agile Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, AGRX annual cash & cash equivalents has changed by -$2.69 M (-51.26%)
What is Agile Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of AGRX is $2.85 M
What is the all time high quarterly cash and cash equivalents for Agile Therapeutics?
Agile Therapeutics all-time high quarterly cash and cash equivalents is $93.92 M
What is Agile Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, AGRX quarterly cash and cash equivalents has changed by $0.00 (0.00%)